ILMN vs LH
Illumina, Inc. and Labcorp, both Healthcare
Illumina, Inc. is the larger company at $25B against $21B. On trailing earnings LH is the cheaper of the two at a P/E of 29.7 against 42.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year ILMN returned +136% against +30% for LH.
| Figure | ILMN | LH |
|---|---|---|
| Last close | $225 | $336 |
| Market cap | $25B | $21B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 42.0 | 29.7 |
| Dividend yield | n/a | 0.9% |
| 1-year return | +136% | +30% |
| 5-year return | -53% | +39% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Illumina, Inc.
Revenue of $1.2B in Q2 2026, net income $207M. Its largest reported line is United States And Canada, 54% of the disclosed total.
Labcorp
Revenue of $3.5B in Q1 2026, net income $278M. Its largest reported line is Diagnostics, 78% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.